Oncology Biomarkers Market Report 2026

Oncology Biomarkers Market Overview

• Oncology Biomarkers market size has reached to $17.3 billion in 2025 • Expected to grow to $33.63 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Rising Prevalence Of Cancer To Drive Market Growth • Market Trend: Innovations In Oncology Biomarkers Enhance Early Detection And Monitoring Of Cancer • North America was the largest region in 2025.

What Is Covered Under Oncology Biomarkers Market?

Oncology biomarkers refer to biological indicators, such as genes, proteins, or other molecules, that can signal the presence of cancer or its progression. They are used to diagnose cancer, predict treatment responses, and monitor disease progression or recurrence. By analyzing these biomarkers, healthcare providers can tailor personalized treatment plans for patients. The main types of oncology biomarkers are protein biomarkers, genetic biomarkers, and others. Protein biomarkers refer to a single protein or multiple proteins used to diagnose an illness, understand prognosis, and monitor a patient's biological response to treatment. The profiling technologies are omics technologies, imaging technologies, immunoassays, bioinformatics, and others. Cancer types include breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, ovarian cancer, liver cancer, and others. The various applications are diagnostics, research and development, prognostics, risk assessment, and others, and are mainly used in hospitals, academic and cancer research institutes, ambulatory surgical centers, and diagnostic laboratories.

What Is The Oncology Biomarkers Market Growth Forecast?

The oncology biomarkers market size is expected to see rapid growth in the next few years. It will grow to $33.63 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing demand for personalized oncology therapies, expansion of AI-driven biomarker discovery, growing investments in cancer genomics, rising adoption of liquid biopsy technologies, increased focus on early cancer detection and monitoring. Major trends in the forecast period include increasing adoption of precision oncology diagnostics, rising use of genetic and protein biomarkers, growing integration of bioinformatics in biomarker analysis, expansion of companion diagnostics development, enhanced focus on personalized cancer treatment.

Global Oncology Biomarkers Market Segmentation

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types 2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types 3) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications 4) By End-User: Hospitals, Academic And Cancer Research Institutes, Diagnostic Laboratories Subsegments: 1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers 2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs) 3) By Other Biomarker Types: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

What Is The Driver Of The Oncology Biomarkers Market?

The rising incidence of cancer is expected to propel the growth of the oncology biomarker market going forward. Cancer is a disease in which some cells of the body grow uncontrollably and slowly spread to the rest of the body. Oncological biomarkers provide more information about the type of cancer by looking at the genes, proteins, and other substances in a person's body. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising incidence of cancer is driving the growth of the oncology biomarkers industry.

Key Players In The Global Oncology Biomarkers Market

Major companies operating in the oncology biomarkers market are F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Epigenomics AG, OncoDNA SA

Global Oncology Biomarkers Market Trends and Insights

Major companies operating in the oncology diagnostics market are focusing on developing advanced biomarker-based assays to improve early cancer detection, monitor minimal residual disease (MRD), and assess patient response to therapies. Minimal residual disease refers to the small number of cancer cells that may remain in the body after treatment, which can lead to recurrence if undetected. For instance, in May 2024, Tempus, a US-based artificial intelligence and precision medicine company, launched its MRD test portfolio, including the xM test and the xM (NeXT Personal Dx) test developed by Personalis. The portfolio features both tumor-naïve and tumor-informed assays designed to detect early cancer recurrence and residual disease, as well as monitor patient response to immunotherapy. By leveraging circulating tumor biomarkers, these assays provide clinicians with sensitive and actionable insights to guide patient management.

What Are Latest Mergers And Acquisitions In The Oncology Biomarkers Market?

In May 2023, Freenome, a US-based, privately held biotech company, acquired Oncimmune Ltd. For an undisclosed amount. This acquisition will help Freenome by providing clinical and commercial resources to complement Freenome’s frontline cancer screening efforts. Further, the acquisition will help augment Freenome’s multi-omics platform to capture a more comprehensive view of the tumor microenvironment. Oncimmune Ltd. Is a UK-based company specializing in developing immunodiagnostics, primarily focusing on immune-oncology, autoimmune disorders, and infectious diseases.

Regional Outlook

North America was the largest region in the oncology biomarkers market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Oncology Biomarkers Market?

The oncology biomarkers market consists of sales of epigenetic biomarkers, metabolic biomarkers and proteomic biomarkers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.